Atrial fibrillation: a contemporary update

Novel ECG wearables and devices

Recent technological advancements have generated a wealth of commercially available wearables and handheld devices that can produce single-lead ECG recordings. These devices are becoming ubiquitous and are being increasingly adopted within clinical practice, enabling patients to provide more accurate symptom–rhythm correlation. As such, they potentially offer increased diagnostic yield for AF detection and could enhance rhythm management. In contrast to the ESC, the National Institute of Health and Care Excellence (NICE) 2021 guidelines still insist on either a 12-lead ECG or ambulatory ECG monitoring to diagnose AF.⁸ However, this has not detracted from the rapid uptake of these direct-to-consumer single-lead ECG recorders by digitally engaged patients and clinicians, who recognise their value in rhythm diagnostics and screening.

Ambulatory ECG monitoring

Diagnosis of paroxysmal AF is best achieved with ambulatory ECG monitoring, usually up to 7 days depending on symptom frequency, or with implantable loop recorders for longer monitoring durations. As well as determining the temporal nature of AF (ie paroxysmal versus persistent), ambulatory ECG monitoring establishes the AF burden and symptom–rhythm correlation, and provides information on ventricular rate control and the occurrence of bradyarrhythmias. These data inform subsequent management decisions regarding optimal treatment approach (rate/rhythm control) and drug titration in response to therapy.

Device-detected AF

High-frequency signals detected on the atrial lead of a pacemaker or cardiac defibrillator can represent underlying AF; however, they are not straightforward to interpret. First, they are susceptible to artefact and noise, which can lead to false positive detection if the recordings are not manually analysed. Second, the prognostic significance with regard to thromboembolism of asymptomatic device-detected AF has yet to be established in robust clinical trials, but might be lower than the stroke risk associated with clinical AF.⁹ The presence of AF symptoms, burden of AF and overall stroke risk profile are likely to influence the clinical significance of these episodes. The ESC advocate consideration of anticoagulation for patients with sustained episodes ≥24 h and a high individual stroke risk.⁷ However, within clinical practice, there remains significant variation in thresholds for initiating anticoagulation and large international multi-centre trials that will attempt to address this are ongoing.

AF screening

Up to one-third of patients with AF are asymptomatic at diagnosis and identifying such patients early could enable prompt initiation of therapeutic anticoagulation to prevent embolic stroke. However, despite a higher detection rate for AF, large randomised controlled trials of AF screening have not demonstrated significant benefit on hard clinical endpoints of stroke and death.¹⁰ Therefore, at present, population-level screening for AF is not recommended, although guidelines do suggest opportunistic or targeted screening for high-risk individuals.⁷

The role of echocardiography

Echocardiography is a key baseline investigation in AF to assess for coexisting left ventricular dysfunction, valvular heart disease and/or left atrial dilatation, the latter being an important marker of AF disease severity that can guide clinicians on the likelihood of success and suitability for rhythm control.

Assessment of thromboembolic risk

Timely assessment of thromboembolic risk is crucial to AF management, given the fivefold increased risk of stroke compared with the general population. Patients with AF are typically risk stratified using the CHA₂DS₂-VASc score (Table 1). Anticoagulation should be considered for AF patients with ≥1 non-sex stroke risk factor (ie CHA₂DS₂-VASc score >0 in men, >1 in women) to reduce risk of cardioembolic stroke. Direct oral anticoagulants should be used in preference to warfarin, given their similar risk reduction for stroke, improved bleeding risk profile and ease of use, with no routine requirement for blood monitoring. However, warfarin remains the gold standard in patients with moderate–severe mitral stenosis¹² and mechanical prosthetic valves.

Assessment of bleeding risk

The decision to start anticoagulation must be balanced against individual patient bleeding risk. The HAS-BLED and ORBIT scores are both validated tools to assess bleeding risk (Table 2). A high bleeding risk should not necessarily preclude anticoagulation but should prompt clinicians to address modifiable bleeding risk factors; it also guides frequency of clinical review once anticoagulation has been started.

Left atrial appendage occlusion

AF-related strokes are consequent to the ineffective contraction of the left atrium, and the left atrial appendage is often a nidus for thrombus formation. Left atrial appendage occlusion is a strategy that could provide effective thromboembolism prophylaxis without the need for oral anticoagulation, potentially in patients with major anticoagulation contraindications. Evidence of overall net benefit for this approach has not been borne out in clinical trials to date and, therefore, careful patient selection is required to determine those most likely to benefit.¹⁶

Pharmacological rate control

Rate control reduces the rapid ventricular rate associated with AF and is typically the initial treatment approach as well as background therapy in nearly all patients with AF. This is achieved using drugs that prolong atrioventricular node (AVN) refractoriness, namely beta blockers, diltiazem, verapamil, digoxin and, less frequently, amiodarone. During rest, a lenient target heart rate <110 beats per minute (bpm) is adequate; however, a strict target of <80 bpm is recommended if patients remain symptomatic, have suspected tachycardiomyopathy or have a biventricular pacemaker.⁷ Rate control can exacerbate bradycardia, particularly with concomitant sinus node dysfunction or AV block (ie tachybrady syndrome); therefore, pacemaker implantation might additionally be required in some cases to enable safe escalation of rate control therapy.

Non-pharmacological rate control: ‘pace and ablate’

Pacing and AVN ablation is a useful strategy for managing drug-refractory permanent AF with high ventricular rates. Disruption of AV nodal conduction dissociates the atria from the ventricles, enabling the ventricular rate to be controlled from a prior implanted pacemaker. This technique is safe and highly effective at managing AF-related symptoms.⁷ The main drawback is irreversible pacemaker dependence; hence, the approach is reserved for select patient groups and avoided in younger patients. Biventricular pacemakers (cardiac resynchronisation therapy; CRT) are commonly implanted to mitigate against the long-term deleterious impact of right ventricular pacing post-AVN ablation.¹⁷ More recently, conduction system pacing by lead implantation into the His bundle or left bundle branch area can achieve more physiological biventricular activation and is a promising alternative approach for long-term pacing.¹⁸

Rhythm control

Rhythm control is the restoration and maintenance of sinus rhythm and is advocated for patients who are symptomatic with AF despite adequate rate control, to improve quality of life. This includes patients who experience significant symptomatic improvement with restoration of sinus rhythm post cardioversion and patients with AF-related exercise intolerance.

The emerging importance of early rhythm control

Historically, trials of rate versus rhythm control have shown comparable efficacy and clinical outcomes between both approaches. Several recent trials comparing outcomes in the modern era of AF ablation have challenged this status quo, suggesting that restoration of sinus rhythm should be a key objective in early AF, not only to improve symptoms, but also to prevent disease progression.¹⁹ Trial data from the past few years indicate a net clinical benefit of early rhythm control (within 1 year of diagnosis) over rate control, with a significant reduction in all-cause mortality, stroke and major adverse cardiovascular events.²⁰ These encouraging data are not yet reflected in current guidelines, but herald a fundamental change in cardiologists' approach to AF rhythm management.

Cardioversion

Synchronised DC cardioversion is the primary approach for emergency AF management in haemodynamically compromised patients and is also performed electively for early persistent AF. Pre-treatment with anti-arrhythmic drugs (AADs), usually amiodarone, can further enhance the likelihood of success and reduces the risk of relapse if continued long term. To reduce the risk of thromboembolic stroke, at least 3 weeks of prior anticoagulation is required before undertaking non-emergency cardioversion if AF onset is beyond 48 hours. Otherwise, the procedure should either be delayed or undertaken with transoesophageal echocardiography to exclude left atrial appendage thrombus.

Anti-arrhythmic drugs

AADs can be used to acutely restore sinus rhythm or as chronic therapy to maintain sinus rhythm in patients with recurrent paroxysmal or early persistent AF. Commonly used drugs include flecainide, propafenone, sotalol, dronedarone and amiodarone. Each drug has an associated organ toxicity profile and pro-arrhythmic risk, which mandates interval monitoring with ECGs, blood tests and imaging. AADs have modest efficacy overall, with the exception of amiodarone, but this is at the expense of serious adverse effects with long-term use. When compared as first-line therapy with catheter ablation, AADs fared worse with increased atrial arrhythmia recurrence, hospitalisations and AF disease progression.^6,21

Catheter ablation

Catheter ablation has emerged as a cornerstone strategy for AF rhythm control. The most established and evidence-based technique is pulmonary vein isolation using radiofrequency or cryoballoon ablation. Trials have demonstrated significant clinical benefit in patients with either paroxysmal or persistent AF in terms of freedom from AF, symptomatic benefit and quality of life.⁷

Patients with paroxysmal AF derive the greatest benefit from ablation with very high single procedure success rates using the latest generation catheter technologies.⁷ Catheter ablation for persistent AF has lower success rates on first-pass ablation, likely because of non-pulmonary vein AF triggers and more established AF substrate. Currently, ESC guidelines recommend catheter ablation for paroxysmal and persistent AF after failure or intolerance of at least one AAD, but ablation can be considered first line in selected symptomatic patients.⁷ Catheter ablation is also recommended in patients with AF and heart failure, especially suspected tachycardiomyopathy, and is associated with reduced mortality and heart failure hospitalisations, as well as improved left ventricular function.^22,23

Advances in ablation and mapping technology have dramatically enhanced the safety and efficacy of AF ablation. Life-threatening complications are rare, the most frequent being cardiac tamponade (∼1%). The most common complications are vascular access related (2–4%). Other complications include pulmonary vein stenosis, phrenic nerve palsy, pericarditis and, rarely, peri-procedural stroke or atrio-oesophageal fistula.

Alternative ablation approaches

Hybrid AF ablation combines catheter ablation with minimally invasive surgical ablation. This is achieved via thoracoscopic access to the epicardial space to deliver ablation directly to the epicardial surface. Early single-centre studies showed impressive results in terms of freedom from AF in patients with persistent AF, although there is a relatively higher complication rate compared with catheter ablation alone.²⁴

Pulsed field ablation (PFA) is a novel non-thermal catheter ablation technique that uses electrical fields to target tissues. Early studies suggest that PFA is very safe with reduced damage to neighbouring structures without detracting from ablation efficacy.²⁵ Randomised controlled trials are awaited to determine how this technique will fare compared with radiofrequency or cryoballoon ablation.